Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 146, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.112488
Keywords
Solid cancer; Prognostic and diagnostic biomarkers; FDA approved protein biomarkers; Detection techniques; Future challenges
Funding
- CSIR/UGC JRF, India [21/06/2015 (i) EU-V]
Ask authors/readers for more resources
Solid cancers are a leading cause of cancer related deaths, and timely detection of resectable or metastatic tumors is crucial for disease prognosis. This review focuses on recent advancements in prognostic and diagnostic biomarkers for early detection of common solid cancers.
Solid cancers are one of the leading causes of cancer related deaths, characterized by rapid growth of tumour, and local and distant metastases. Current advances on multimodality care have substantially improved local control and metastasis-free survival of patients by resection of primary tumour. The major concern in disease prognosis is the timely detection of resectable or metastatic tumour, thus reinforcing the need for identification of biomarkers for premalignant lesions of solid cancer. This ultimately improves the outcome for the patients. Therefore, the purpose of this review is to update the recent advancements on prognostic and diagnostic bio-markers to enhance early detection of common solid cancers including, breast, lung, colorectal, prostate and stomach cancer. We also provide an insight into Food and Drug Administration (FDA)-approved solid cancers biomarkers; various conventional techniques used for detection of prognostic and diagnostic biomarkers and discuss approaches to turn challenges in this field into opportunities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available